What Makes BillionToOne (BLLN) a Revolutionizer in Genetic Testing?

In its first-quarter 2026 capitalist letter, Baron Health Care Fund highlighted BillionToOne, Inc. (NASDAQ:BLLN). BillionToOne, Inc. (NASDAQ:BLLN) is simply a precision diagnostics institution specializing successful molecular diagnostics. On May 1, 2026, BillionToOne, Inc. (NASDAQ:BLLN) closed astatine $77.49 per share. One-month instrumentality of BillionToOne, Inc. (NASDAQ:BLLN) was -9.37%, and YTD its shares mislaid 5.32%. BillionToOne, Inc. (NASDAQ:BLLN) has a marketplace capitalization of $3.56 billion.

Baron Health Care Fund stated the pursuing regarding BillionToOne, Inc. (NASDAQ:BLLN) successful its Q1 2026 capitalist letter:

"We added to the Fund’s concern successful BillionToOne, Inc. (NASDAQ:BLLN), a diagnostics institution that is disrupting the marketplace with much close prenatal and oncology familial tests. At the halfway is the company's innovative quantitative counting template (QCT) technology, which allows BillionToOne to accurately number the fig of mutation copies astatine a single-gene level. BillionToOne generates the immense bulk of its gross contiguous from UNITY, which is simply a differentiated prenatal familial test. Traditional prenatal tests tin cheque for chromosomal abnormalities similar Down syndrome but necessitate much invasive investigating to trial for azygous cistron inherited disorders. UNITY is simply a azygous humor gully from the ma that tin surface for chromosomal problems and supply an close hazard appraisal for recessive single-gene disorders. BillionToOne has already captured 15% of the $2 billion-plus U.S. prenatal screening marketplace (according to our estimates) successful a abbreviated play of time, and we expect them to proceed to summation share. BillionToOne is besides making aboriginal headways successful oncology, which represents a $50 billion-plus full addressable market, according to our estimates. The aforesaid QCT exertion powers BillionToOne's NORTHSTAR SELECT therapy enactment test, which tin find 51% to 109% much actionable mutations than rival tests. The trial has a overmuch little lower-limit-of-detection compared to competitors and tin observe operator mutations adjacent erstwhile the allele transcript fig is low. BillionToOne besides offers NORTHSTAR RESPONSE, which is simply a caller benignant of trial that tin observe subtle alteration successful a crab patient's tumor load and tin way whether the diligent is responding to therapy. We are optimistic that much information astir RESPONSE this twelvemonth volition alteration wide Medicare reimbursement for the test. BillionToOne's motorboat successful oncology is inactive nascent, but we deliberation this merchandise differentiation volition assistance BillionToOne seizure stock successful this ample and increasing market. Impressively, BillionToOne has accomplished each of this portion maintaining fiscal discipline. The institution has 70% gross margins and has already achieved GAAP profitability and affirmative escaped currency flow."